Journals / European Archives of Medical Research / 2022 / Cilt: 38 - Sayı: 1

Contribution of Lower Extremity 68Ga PSMA PET/CT Imaging to Diagnosis and Treatment in Prostate Cancer

Pages
36–41
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Considering the loss of time caused by additional acquisitons in the clinic, the radiation dose exposure of the patient and the outcomes in this study, it may be possible to say that the lower extremity acquisitons are not effectiv

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is to evaluate the effectiveness of routine additional acquisitions for lower extremity in the diagnosis and treatment of patients undergoing 68Ga prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT).
📊
Key Findings & Data:Methods: The files of 59 prostate cancer patients who underwent additional acquisition of the lower extremities in addition to the vertexupper thigh in 68Ga PSMA PET/CT studies were included in the study.
💡
Conclusion & Impact:Conclusion: Considering the loss of time caused by additional acquisitons in the clinic, the radiation dose exposure of the patient and the outcomes in this study, it may be possible to say that the lower extremity acquisitons are not effectiv
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study is to evaluate the effectiveness of routine additional acquisitions for lower extremity in the diagnosis and treatment of patients undergoing 68Ga prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT). Methods: The files of 59 prostate cancer patients who underwent additional acquisition of the lower extremities in addition to the vertexupper thigh in 68Ga PSMA PET/CT studies were included in the study. In our study, patients with both lower limb acquisition on clinical suspicion and with routine lower limb acquisition were included. Along with the difference in the effectiveness of the lower limb acquisition between these two arms, the efficacy and clinical utility of the additional acquisiton were evaluated in the entire sample. Results: The rate of metastasis detected in the group with lower limb acquisiton with clinical suspicion (31.1%) is higher than in the other group (7.6%). However, metastases detected in both groups do not cause changes in the treatment. Conclusion: Considering the loss of time caused by additional acquisitons in the clinic, the radiation dose exposure of the patient and the outcomes in this study, it may be possible to say that the lower extremity acquisitons are not effectiv

🔖

Cite This Article

KARYAĞAR, S. S., GÜVEN, O., ÖZÜLKER, F., ÖZÜLKER, T., SARAÇOĞLU, S. (2022). Contribution of Lower Extremity 68Ga PSMA PET/CT Imaging to Diagnosis and Treatment in Prostate Cancer. European Archives of Medical Research, Cilt: 38 - Sayı: 1, 36–41. https://ajindex.com/articles/510286

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394- 424. Erratum in: CA Cancer J Clin 2020;70:313
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34
  3. T.C. Halk Sağlığı Kurumu. Türkiye Kanser İstatistikleri 2015. T.C. Sağlık Bakanlığı Halk Sağlığı Müdürlüğü. 2018
  4. Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-83
  5. Shou J, Zhang Q, Wang S, Zhang D. The prognosis of different distant metastases pattern in prostate cancer: a population based retrospective study. Prostate 2018;78:491-7
  6. Hupe MC, Philippi C, Roth D, Kümpers C, Ribbat-Idel J, Becker F, et al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol 2018;8:623
  7. Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med 2019;60:786- 93
  8. Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics 2018;38:200-17
  9. Munro L. Basics of Radiation Protection How to Achieve ALARA: Working Tips and Guidelines. Ostensen H, Ingolfsdottir G, editors. World Health Organization. 2004
  10. Plouznikoff N, Arsenault F. Clinical relevance of 18F-FDG PET/CT lowerlimb imaging in patients with malignant cutaneous melanoma. Nucl Med Commun 2017;38:1103-8
  11. Webb HR, Latifi HR, Griffeth LK. Utility of whole-body (head-to-toe) PET/ CT in the evaluation of melanoma and sarcoma patients. Nucl Med Commun 2018;39:68-73
  12. Querellou S, Keromnes N, Abgral R, Sassolas B, Le Roux PY, Cavarec MB, et al. Clinical and therapeutic impact of 18F-FDG PET/CT wholebody acquisition including lower limbs in patients with malignant melanoma. Nucl Med Commun 2010;31:766-72
  13. Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostatespecific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 2016;70:92